Glenmark Pharmaceuticals to launch Brukinsa (zanubrutinib) in India after DCGI approval, offering treatment for five B-cell blood cancers with fewer cardiac side effects and flexible dosing options.

Glenmark is set to launch a generic version of Teva’s Adderall tablets in strengths ranging from 5 mg to 30 mg, with distribution set to begin in May 2025. The company will launch ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch[1] of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine ...

Glenmark's Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg ...

Glenmark is recalling over 25 products due to CGMP deviations, Sun Pharma due to 'cross contamination,' and Zydus due to CGMP deviations.

Glenmark Pharmaceuticals on Monday (February 24, 2025) said it will pay USD 7 million to three entities to settle lawsuits in the U.S. related to generic drugs. In a regulatory filing, the Mumbai ...

Mahwah, N.J.-based Glenmark recently agreed to pay $25 million, based on its ability to pay, to resolve its alleged liability under the False Claims Act for conspiring to fix the price of a ...

Glenmark Pharmaceuticals Inc. is voluntarily recalling 114 batches of Potassium Chloride Extended-Release Capsules USP (750 mg) 10 mEq K to the consumer level in the U.S. because of failed ...

Glenmark’s potassium chloride capsules are used to treat patients with low potassium, or hypokalemia. For patients who consistently use the drug—and especially in those with other underlying ...

For the fourth quarter ended March 31, 2023, Glenmark’s consolidated revenue stood at ₹3,063 crore, as compared to ₹3,000 crore, up 2.1 percent over the same period in the previous year.

Glenmark Specialty SA, a subsidiary of Glenmark Pharma, announced an exclusive marketing and distribution agreement with BeiGene, a global oncology company. Under this agreement, Glenmark will ...

Glenmark Pharmaceuticals has entered (PDF) the subcutaneous checkpoint inhibitor space, agreeing to pay "low double-digit millions" for the chance to launch envafolimab in markets including India ...